Claus F. Vogelmeier , Gerard J. Criner , Fernando J. Martinez , Antonio Anzueto , Peter J. Barnes , Jean Bourbeau , Bartolome R. Celli , Rongchang Chen , Marc Decramer , Leonardo M. Fabbri , Peter Frith , David M.G. Halpin , M. Victorina López Varela , Masaharu Nishimura , Nicolas Roche , Roberto Rodriguez-Roisin , Don D. Sin , Dave Singh , Robert Stockley , Jørgen Vestbo , Jadwiga A. Wedzicha , Alvar Agusti
March 08 2017
January 30 2017
This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.